POINT Biopharma Global Inc.
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand …
Biotechnology
US, Indianapolis [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about POINT Biopharma Global Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2022 | - | 0.950 | - | 240 | - | 97 | - | 205 | - | 205 | - | 167 |
| 2023 | - | -1.120 | - | 16 | - | -106 | - | 14 | - | 14 | - | 11 |
| 2024 | - | -1.400 | - | 144 | - | -93 | - | 123 | - | 123 | - | 100 |
| 2025 | - | 0.239 | - | 218 | - | 37 | - | 187 | - | 186 | - | 152 |